Avantor downgraded by Barclays with a new price target
$AVTR
Biotechnology: Laboratory Analytical Instruments
Industrials
Barclays downgraded Avantor from Overweight to Equal Weight and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2025 | Outperform → Mkt Perform | Raymond James | |
| 10/30/2025 | $12.00 | Overweight → Equal Weight | Barclays |
| 10/30/2025 | $12.00 | Overweight → Neutral | Analyst |
| 8/1/2025 | Buy → Hold | Jefferies | |
| 4/29/2025 | $14.00 | Buy → Neutral | Goldman |
| 4/28/2025 | $15.50 | Buy → Hold | TD Cowen |
| 4/28/2025 | $14.00 | Buy → Hold | Stifel |
| 4/28/2025 | Overweight → Equal-Weight | Morgan Stanley |
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
3 - Avantor, Inc. (0001722482) (Issuer)
8-K - Avantor, Inc. (0001722482) (Filer)
10-Q - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
Raymond James downgraded Avantor from Outperform to Mkt Perform
Barclays downgraded Avantor from Overweight to Equal Weight and set a new price target of $12.00
Analyst downgraded Avantor from Overweight to Neutral and set a new price target of $12.00
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
RADNOR, Pa., Nov. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its newest Centralized Service Center (CSC) serving the Greater Boston area. The new facility in Watertown, Massachusetts, addresses the shortage of laboratory space for scientific research by enabling organizations to maximize their research footprint, accelerate discoveries, and reduce operational complexity through off-site support for essential but non-core services such as media and buffer preparation, chemical management,
RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit
Integrated sterile sampling and PUPSIT solutions streamline bioprocessing, enhance flexibility, and reduce risk while accelerating in-process decisions RADNOR, Pa., Oct. 30, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of its pre-engineered PUPSIT (pre-use, post-sterilization integrity testing) assemblies and comprehensive sterile sampling suite. Designed to simplify qualification steps, reduce contamination risk, and support faster in-process decisions, the new suite of products gives manufacturers greater flexibility in ho
RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit
Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa., Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T. Lucier to its Board of Directors. Mr. Lucier brings significant experience and broad expertise across the healthcare landscape to the Avantor Board. He founded and serves as Executive Chairman and CEO of Corza Medical, a leading global manufact
RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform
Net sales of $1.62 billion, decrease of 5%Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 millionAdjusted EBITDA of $268 million; adjusted EPS of $0.22Operating cash flow of $207 million; free cash flow of $172 millionCompany announces $500 million share repurchase authorization, reflecting confidence in cash generation and commitment to driving long-term shareholder valueRADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its t
RADNOR, Pa., Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global
Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)